CA3102979A1 - Methods and compositions for preventing or treating calciphylaxis - Google Patents

Methods and compositions for preventing or treating calciphylaxis Download PDF

Info

Publication number
CA3102979A1
CA3102979A1 CA3102979A CA3102979A CA3102979A1 CA 3102979 A1 CA3102979 A1 CA 3102979A1 CA 3102979 A CA3102979 A CA 3102979A CA 3102979 A CA3102979 A CA 3102979A CA 3102979 A1 CA3102979 A1 CA 3102979A1
Authority
CA
Canada
Prior art keywords
subject
mkh2
administration
calciphylaxis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102979A
Other languages
English (en)
French (fr)
Inventor
James A. TUMLIN
Paul L. Darke
John M. RUDEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizon Pharma Inc
Original Assignee
Epizon Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizon Pharma Inc filed Critical Epizon Pharma Inc
Publication of CA3102979A1 publication Critical patent/CA3102979A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3102979A 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis Pending CA3102979A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682794P 2018-06-08 2018-06-08
US62/682,794 2018-06-08
PCT/US2019/036139 WO2019237054A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Publications (1)

Publication Number Publication Date
CA3102979A1 true CA3102979A1 (en) 2019-12-12

Family

ID=68763971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102979A Pending CA3102979A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Country Status (11)

Country Link
US (7) US10736858B2 (OSRAM)
EP (1) EP3801478A4 (OSRAM)
JP (1) JP2021527129A (OSRAM)
KR (1) KR20210018422A (OSRAM)
CN (1) CN112955131A (OSRAM)
AU (1) AU2019282421B2 (OSRAM)
CA (1) CA3102979A1 (OSRAM)
IL (1) IL279246B2 (OSRAM)
MX (2) MX2020013301A (OSRAM)
SG (1) SG11202012055PA (OSRAM)
WO (1) WO2019237054A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210018423A (ko) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물
MX2020013301A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Metodos y composiciones para prevenir o tratar calcifilaxis.
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
MX2021008076A (es) * 2019-01-04 2021-12-10 Nattopharma As Terapia de combinacion de aglutinantes de fosfato y vitamina k.
CN112691058A (zh) * 2020-12-31 2021-04-23 玉溪健坤生物药业有限公司 一种含还原型维生素k2的牙膏及其制备方法
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
US20050123603A1 (en) 2003-09-26 2005-06-09 Natural Asa Natural menaquinone 7 compositions
SI1728507T1 (sl) 2005-06-03 2011-07-29 Nattopharma Asa Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil
WO2007095630A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California New ubiquinone analogs and methods of use
JP5827784B2 (ja) * 2006-07-14 2015-12-02 ナットファルマ エーエスエー ビタミンｋ２を含む医薬及び栄養補助製品
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
AU2011324792A1 (en) * 2010-11-01 2013-05-30 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin MK-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
ES2869202T3 (es) 2012-06-18 2021-10-25 Fresenius Kabi Deutschland Gmbh Sistema de cánula para vía para la punción de vías centrales de acceso subcutáneo
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
US9464021B2 (en) 2013-11-01 2016-10-11 Dilip S. Mehta Method of preparation of stereospecific quinone derivatives
EP3258924A2 (en) 2015-02-20 2017-12-27 VitaK B.V. Vitamin k and capillary function
GEP20197040B (en) 2015-03-20 2019-11-11 Gnosis Spa Solid forms of menaquinols
CN206387961U (zh) 2016-12-30 2017-08-08 孙淑芬 头戴显示设备
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
US11407704B2 (en) 2018-04-06 2022-08-09 Siec Badawcza Lukasiewicz-Instytut Chemii Przemyslowej Imienia Profesora Ignacego Moscickiego Process of vitamin K2 derivatives preparation
MX2020013301A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Metodos y composiciones para prevenir o tratar calcifilaxis.
KR20210018423A (ko) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment

Also Published As

Publication number Publication date
MX2024010211A (es) 2024-09-02
US20200306207A1 (en) 2020-10-01
IL279246B2 (en) 2023-08-01
US20200360301A1 (en) 2020-11-19
US20200306208A1 (en) 2020-10-01
US10925838B2 (en) 2021-02-23
US20200306206A1 (en) 2020-10-01
US11065212B2 (en) 2021-07-20
US10987320B2 (en) 2021-04-27
JP2021527129A (ja) 2021-10-11
WO2019237054A1 (en) 2019-12-12
AU2019282421B2 (en) 2025-01-09
US20210378987A1 (en) 2021-12-09
KR20210018422A (ko) 2021-02-17
US20240041794A1 (en) 2024-02-08
MX2020013301A (es) 2021-05-12
IL279246A (en) 2021-01-31
AU2019282421A1 (en) 2021-01-07
US20190374483A1 (en) 2019-12-12
US12433854B2 (en) 2025-10-07
US10736858B2 (en) 2020-08-11
EP3801478A4 (en) 2022-02-23
US10940123B2 (en) 2021-03-09
CN112955131A (zh) 2021-06-11
SG11202012055PA (en) 2021-01-28
EP3801478A1 (en) 2021-04-14
IL279246B1 (en) 2023-04-01
US11793773B2 (en) 2023-10-24

Similar Documents

Publication Publication Date Title
US12433854B2 (en) Methods and compositions for preventing or treating calciphylaxis
US12377060B2 (en) Methods and compositions for preventing or treating tissue calcification
JP5827784B2 (ja) ビタミンｋ２を含む医薬及び栄養補助製品

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240606

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250617

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20251017

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251215

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260122

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260122